Direct medical care costs associated with patients diagnosed with chronic HCV

Hepatitis Monthly

Volumn 13, Issue 5, 2013, Pages

  Ashtari, Sara ^a   Vahedi, Mohsen ^b   Pourhoseingholi, Mohammad Amin ^a   Karkhane, Maryam ^a   Kimiia, Zahra ^a   Pourhoseingholi, Asma ^a   Safaee, Azadeh ^a   Moghimi Dehkordi, Bijan ^a   Zali, Mohammad Reza ^a   Alavian, Seyed Moayed ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic; Health care costs; Hepatitis c; Peginterferon Alfa 2a

Indexed keywords

ALPHA2B INTERFERON PLUS RIBAVIRIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE COURSE; DRUG COST; FEMALE; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE;

EID: 84877679045     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.8415     Document Type: Article

References (37)

1. Alavian SM. We need a new national approach to control hepatitis C: It is becoming too late. Hepat Mon. 2008;8(3):165-169. [PubMed]
2. Alavian SM. Hepatitis C infection in Iran; A review article. Iran J Clin Infect Dis. 2009;4(1):47-59.
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-2441. [PubMed]
4. Brown RS, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 2003;9(11):S10-13. [PubMed]
5. Alavian SM, Lankarani KB, Alaei-Andabili SH, Pouryasin A, Ebrahimi Daryani N, Nassiri Toosi M, et al. Treatment of chronic hepatitis C Infection: Updated of the Recommendation from Scientific Leaders' Meeting-28th July 2011-tehran, IR iRAN. Hepat Mon. 2011;11(9):703-713.
6. Alavian SM, Ahmadzad Asl M, Lankarani KB, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C Infection in the General Population of Iran: A Systematic Review. Hepat Mon. 2009;9(3):211-223.
7. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010;14 Suppl 3:e113-116. [PubMed]
8. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005;8(2):84-90.
9. Williams R. Global challenges in liver disease. Hepatology. 2006;44(3):521-6. [PubMed]
10. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26(3):34S-8S. [PubMed]
11. El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ. 2005;6(2):159-165. [PubMed]
12. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN. Gastro Hepat. 2010;3(1):5-14.
13. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81. [PubMed]
14. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006;101(9):2076-2089. [PubMed]
15. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001;161(18):2231-2237. [PubMed]
16. Dienstag JL, Isselbacher KJ. Harrison's principles of internal medicine. 2005.
17. Kenneth W, Lin MD, Jeffrey T, Kirchner DO. Lancaster, American Family Physicisn. Pennsylvania. 2004;69:75-82.
18. Rice DP. Cost of illness studies: what is good about them? Inj Pre. 2000;6(3):175-176.
19. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407-413. [PubMed]
20. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8(2):192-199. [PubMed]
21. Ahmadipour MH, Alavian SM, Amini S, Azadmanesh K. Hepatitis C Virus Genotypes. Hepat Mon. 2003;5(3):77-82.
22. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of pegylated interferon alpha-2a AND alpha-2b in patients with genotype 1 chronic Hepatitis C: a meta-analysis. BMC Infect Dis. 2012;12(1):357. [PubMed]
23. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an a la carte combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000;31(1):211-218. [PubMed]
24. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362(9401):2095-2100. [PubMed]
25. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982. [PubMed]
26. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-1171. [PubMed]
27. Center for Disease Control and Prevention. Cost analysis: Introduction/CDC Econ Eval Tutorials. Available from: http://www.cdcgov/owcd/eet/Cost/3.html
28. Moghimi-Dehkordi B, Vahedi M, Khoshkrood Mansoori B, Kasaeian A, Safaee A, Habibi M, et al. Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study. Arab J Gastroenterol. 2011;12(2):86-89. [PubMed]
29. Moghimi-Dehkordi B, Vahedi M, Pourhoseingholi MA, Khoshkrood Mansoori B, Safaee A, Habibi M, et al. Economic burden attributable to functional bowel disorders in Iran: a cross-sectional population-based study. J Dig Dis. 2011;12(5):384-392. [PubMed]
30. Mohaghegh Shalmani H, Soori H, Khoshkrood Mansoori B, Vahedi M, Moghimi-Dehkordi B, Pourhoseingholi MA, et al. Direct and indirect medical costs of functional constipation: a population-based study. Int J Colorectal Dis. 2011;26(4):515-522. [PubMed]
31. Roshandel D, Rezailashkajani M, Shafaee S, Zali MR. A cost analysis of functional bowel disorders in Iran. Int J Colorectal Dis. 2007;22(7):791-799. [PubMed]
32. Medical Laws and Tariffs. [The price list by Iranian Cabinet of the Public Health Centers]. 2010; Available from: http://www.irteb.com/
33. Iranian Ministry of Health and Medical Education. [List of price of drugs]. 2010; Available from: http://fdo.behdasht.gov.ir/
34. Trading Economic Website. 2010; Available from: http://www.tradingeconomic.com.
35. Amini S, Abadi MMFM, Alavian SM, Joulaie M, Ahmadipour MH. Distribution of Hepatitis C Virus Genotypes in Iran: A Population-Based Study. Hepat Mon. 2009;9(2):95-102. [PubMed]
36. Palumbo E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther Adv Chronic Dis. 2011;2(1):39-45. [PubMed]
37. Iranian Databases of Census Publication. 2006; Available from: http://amar.sci.org.ir/